We and others have demonstrated that NAMPT inhibitors exhibit high efficacy against a wide range of human solid tumors and blood cancers, without significant toxicity to laboratory animal models [19,29,36,42,43,44,45,46,47,48,49]. This evidence concerns the gene NAMPT and hematopoietic and lymphoid system neoplasm.